These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2417077)

  • 1. Antigenic heterogeneity of Escherichia coli verotoxins.
    Karmali MA; Petric M; Louie S; Cheung R
    Lancet; 1986 Jan; 1(8473):164-5. PubMed ID: 2417077
    [No Abstract]   [Full Text] [Related]  

  • 2. Bacterial antigenic cross-reactions and haemolytic uraemic syndrome.
    Chart H; Scotland SM; Rowe B
    Lancet; 1988 Aug; 2(8609):510-1. PubMed ID: 2900432
    [No Abstract]   [Full Text] [Related]  

  • 3. Serological differences between verocytotoxin 2 and shiga-like toxin II.
    Head SC; Karmali MA; Roscoe ME; Petric M; Strockbine NA; Wachsmuth IK
    Lancet; 1988 Sep; 2(8613):751. PubMed ID: 2901605
    [No Abstract]   [Full Text] [Related]  

  • 4. Production and characterisation of monoclonal antibodies to Verotoxins 1 and 2 from Escherichia coli of serotype O 157:H7.
    Padhye VV; Zhao T; Doyle MP
    J Med Microbiol; 1989 Nov; 30(3):219-26. PubMed ID: 2479749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nature of immunity to the Escherichia coli Shiga toxins (verocytotoxins) and options for toxoid immunization.
    Karmali MA
    Jpn J Med Sci Biol; 1998; 51 Suppl():S26-35. PubMed ID: 10211434
    [No Abstract]   [Full Text] [Related]  

  • 6. Production, characterization and immunodiagnostic application of a monoclonal antibody to Shiga toxin.
    Qadri F; Mohi MG; Azim T; Faruque SM; Kabir AK; Albert MJ
    J Diarrhoeal Dis Res; 1996 Jun; 14(2):95-100. PubMed ID: 8870402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with haemolytic uraemic syndrome caused by Escherichia coli O157: absence of antibodies to Vero cytotoxin 1 (VT1) or VT2.
    Chart H; Law D; Rowe B; Acheson DW
    J Clin Pathol; 1993 Nov; 46(11):1053-4. PubMed ID: 8254096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of serum antibodies to Verotoxins 1 and 2 among healthy adults in Japan.
    Takeda T; Nakao H; Yamanaka T; Igarashi T; Takeda Y; Kobayashi N
    J Infect; 1993 Sep; 27(2):211-3. PubMed ID: 8228310
    [No Abstract]   [Full Text] [Related]  

  • 9. Verocytotoxin-producing Escherichia coli in children with hemolytic uremic syndrome in the Czech Republic.
    Bielaszewska M; Janda J; Blahová K; Feber J; Potuzník V; Soucková A
    Clin Nephrol; 1996 Jul; 46(1):42-4. PubMed ID: 8832150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A longitudinal study of Vero cytotoxin producing Escherichia coli in cattle calves in Sri Lanka.
    Tokhi AM; Peiris JS; Scotland SM; Willshaw GA; Smith HR; Cheasty T
    Epidemiol Infect; 1993 Apr; 110(2):197-208. PubMed ID: 8472764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Escherichia coli Shiga-like toxins (verotoxins) in pigs.
    Gannon VP; Gyles CL; Wilcock BP
    Can J Vet Res; 1989 Jul; 53(3):306-12. PubMed ID: 2670167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the National Institutes of Health. Summary of the International Symposium and Workshop on Infections due to Verocytotoxin (Shiga-like toxin)-producing Escherichia coli.
    Edelman R; Karmali MA; Fleming PA
    J Infect Dis; 1988 May; 157(5):1102-4. PubMed ID: 3283259
    [No Abstract]   [Full Text] [Related]  

  • 13. Protection against verocytotoxin in mice induced by liposome-coupled verocytotoxin.
    Naito S; Horino A; Komiya T; Fukuda Y; Takahashi M; Ami Y; Suzaki Y; Satoh S; Gondaira F; Sugiyama J; Nakano Y; Mori M; Awai K; Nishinohara S; Komuro K; Uchida T
    Int Arch Allergy Immunol; 1997 Nov; 114(3):293-7. PubMed ID: 9363912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study.
    Bitzan M; Ludwig K; Klemt M; König H; Büren J; Müller-Wiefel DE
    Epidemiol Infect; 1993 Apr; 110(2):183-96. PubMed ID: 8472763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the antigenic difference between Vero toxin 2 (VT2) and VT2 variant (VT2vh) of Verotoxin-producing Escherichia coli by a site-directed mutagenesis.
    Ito H; Nishibuchi M; Takeda Y
    FEMS Microbiol Lett; 1991 Mar; 63(1):27-30. PubMed ID: 2044938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A spectrum of verocytotoxigenic Escherichia coli.
    Bettelheim KA
    J Med Microbiol; 1998 Dec; 47(12):1037-8. PubMed ID: 9856638
    [No Abstract]   [Full Text] [Related]  

  • 17. Diarrhoea associated with Escherichia coli O157 which do not produce verocytotoxins.
    Paul M; Ghosh AR; Nair GB; Bhattacharya SK; Pal SC; Sen D
    J Diarrhoeal Dis Res; 1991 Jun; 9(2):123-4. PubMed ID: 1918835
    [No Abstract]   [Full Text] [Related]  

  • 18. [Coliform bacilli which produce cytotoxins: importance in veterinary medicine and public health].
    De Rycke J
    Ann Rech Vet; 1991; 22(2):105-26. PubMed ID: 1897865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors and markers of virulence in Escherichia coli from human septicemia.
    Cherifi A; Contrepois M; Picard B; Goullet P; de Rycke J; Fairbrother J; Barnouin J
    FEMS Microbiol Lett; 1990 Aug; 58(3):279-83. PubMed ID: 2227363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of protection against oral infection with cytotoxin-producing Escherichia coli O157:H7 in mice by shiga-like toxin-liposome conjugate.
    Fukuda T; Kimiya T; Takahashi M; Arakawa Y; Ami Y; Suzaki Y; Naito S; Horino A; Nagata N; Satoh S; Gondaira F; Sugiyama J; Nakano Y; Mori M; Nishinohara S; Komuro K; Uchida T
    Int Arch Allergy Immunol; 1998 Aug; 116(4):313-7. PubMed ID: 9693282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.